Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV
Por um escritor misterioso
Descrição
Current clinical status of new COVID-19 vaccines and immunotherapy
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19: Molecular Therapy
COVID-19 Vaccine Frontrunners and Their Nanotechnology Design
An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19), Cellular & Molecular Biology Letters
Immunogenicity of a DNA vaccine candidate for COVID-19
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
Delving into revolutionary SARS-CoV-2 vaccine approaches: Molecular and virological examinations; principles of SARS-CoV-2 vaccine platform
Vaccines, Free Full-Text
Immunogenicity of a DNA vaccine candidate for COVID-19
Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model
Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans
A brief review on DNA vaccines in the era of COVID-19
Phase 2 trial shows INO-4800 SARS-CoV-2 DNA vaccine safe and tolerable in adults
Frontiers The Current Status of COVID-19 Vaccines
COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models - ScienceDirect
de
por adulto (o preço varia de acordo com o tamanho do grupo)
